miR-601 is a prognostic marker and suppresses cell growth and invasion by targeting PTP4A1 in breast cancer |
| |
| Institution: | 1. Department of Basic Medicine, Guiyang College of Traditional Chinese Medicine, Guiyang 550002, People’s Republic of China;2. Department of Radiation Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, People’s Republic of China;3. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, People’s Republic of China;4. Department of General Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, People’s Republic of China;1. Department of Laboratory Medicine, National University Hospital, Singapore;2. National University Cancer Institute, Singapore;3. Department of Pathology, National University, Singapore;4. Department of Surgery, National University Hospital, Singapore;1. Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China;2. Department of General Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, China;3. Department of Science and Research, Affiliated Hospital of Hebei University, Baoding, 071000, China;4. Department of Pathology, Health Science Center, Hebei University, Baoding, 071000, China;5. Department of Medical Oncology, The First Hospital of ShiJiazhuang, ShiJiazhuang, 050010, China;6. Department of Clinical Epidemiology, The First Hospital of Jilin University, Changchun, 130021, China;1. Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt;2. Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt;1. Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China;2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;3. Department of Gastroenterology, Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China;4. Department of General Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;5. State Key Laboratory for Oncogenes and Related Genes, Division of Gastroenterology and Hepatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;6. Department of General Surgery, Wenzhou No. 3 Clinical Institute of Wenzhou Medical University, Wenzhou People’s Hospital, Wenzhou, Zhejiang, China;7. Central Laboratory of Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China |
| |
| Abstract: | MicroRNAs (miRNA) play important roles in the initiation and progression of breast cancer. Here, we investigated the role of miR-601 in breast cancer and found that its expression was significantly down-regulated in breast cancer tissues compared with matched adjacent non-cancerous breast tissues. Moreover, we found that down-regulation of miR-601 was closely associated with distant metastasis and poor distant metastasis-free survival in breast cancer. In addition, miR-601 levels were inversely correlated with metastatic potential of human breast cancer cell lines. Further experiments showed that ectopic overexpression of miR-601 suppressed breast cancer cell proliferation, migration and invasion, whereas miR-601 knockdown promoted breast cancer cell proliferation, migration and invasion. Furthermore, protein tyrosine phosphatase type IVA 1 (PTP4A1) was identified as a direct target of miR-601. Overexpression of miR-601 repressed PTP4A1 mRNA and protein expression. Conversely, inhibition of miR-601 increased PTP4A1 mRNA and protein expression. Taken together, our data suggest that miR-601 inhibits growth and invasion of breast cancer cells by targeting PTP4A1 and that miR-601 is a potential biomarker for prognosis and therapeutic target in breast cancer. |
| |
| Keywords: | Breast cancer miR-601 PTP4A1 Metastasis Prognosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
